• Recruiting

NCT04398680: Phase 1: Belantamab Mafodotin With Normal & Impaired Hepatic Function (DREAMM 13) RRMM

Updated: Sep 19

NCT04398680: Phase 1: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM 13)

dreamm 13 belantamab bcma therapy myeloma

NCT04398680: Phase 1: A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function (DREAMM 13)


The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.


Sponsor

GlaxoSmithKline

 

ClinicalTrials.gov Identifier: NCT04398680 Official Title: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)

First Posted : May 21, 2020

Click here for details on ClinicalTrials.gov


DREAMM Clinical Trial Program (dreammtrials.com)

 

Belantamab mafodotin : National Cancer Institute

Belantamab mafodotin : MedlinePlus Drug Information

GSK2857916

 

Drug: Belantamab mafodotin

 

Locations

United States, Arizona

United States, California

United States, Florida

United States, Illinois

United States, Kansas

United States, Maryland

United States, New Jersey

United States, Pennsylvania

United States, Texas

United States, Wisconsin


Europe

Asia

Greece

Korea, Republic of

 

RELATED POSTS


DREAMM-1

NCT02064387: Phase 1 -Safety Pharm.kinetics Pharm.dynamics Img. & Cl. Activity GSK2857916 - DREAMM-1

Click here for details


DREAMM-2

NCT03525678: Phase 2 - Two Doses of GSK2857916 in Myeloma who have failed Anti-CD38 Ab. DREAMM 2

Click here for details


DREAMM-3

NCT04162210: Phase 3 - Belantamab Mafodotin Vs Pomalidomide + Low-dose Dexamethasone (Pom/Dex) RRMM

Click here for details


DREAMM-4

NCT03848845: Phase 1/2: GSK2857916 in Combination With Pembrolizumab in RRMM Myeloma- DREAMM 4

Click here for details


DREAMM-5

NCT04126200: Phase 1/2 - Belantamab Mafodotin as Monotherapy & With Anti-cancer Rx (RRMM) (DREAMM 5)

Click here for details


DREAMM-6

NCT03544281: Phase 2: GSK2857916 /Len/Dex Vs GSK2857916/Bortezomib/Dex - RRMM Myeloma - DREAMM 6

Click here for details


DREAMM-7

NCT04246047: Phase 3: Belantamab Mafodotin, Bortezomib and Dex RRMM Myeloma (DREAMM 7)

Click here for details


DREAMM-8

NCT04484623: Phase 3 - Belantamab Mafodotin & Pom/Dex (Pd) Vs Bortezomib & Pd in Ref. MM (DREAMM 8)

Click here for details


DREAMM-9

NCT04091126: Phase 1 - Belantamab Mafodotin + Standard of Care New Multiple Myeloma (DREAMM 9) NDMM

Click here for details


DREAMM-12

NCT04398745: Phase 1: Belantamab Mafodotin With Normal and Varying Degree of Impaired Renal Function

Click here for details


DREAMM-14

NCT05064358: Phase 2 - Alternative Dosing Regimens of Belantamab Mafodotin RRMM - (DREAMM 14)

Click here for details

 

NCT038282: Phase 1 - Dose Esc Study Belantamab mafodotin (GSK2857916) in Japanese With Refr MM

Click here for details


NCT03715478: Phase 1/2: Multi-Center Study of GSK2857916 With Pomalidomide & Dex - Algonquin trial

Click here for details


NCT04680468: Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant & Maintenance

Click here for details


NCT04822337: Phase 1/2 - Study of Carfilzomib, Len, Dex & Belantamab Mafodotin in Multiple Myeloma

Click here for details


NCT04802356: Phase 2: Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma

Click here for details


NCT04808037: Phase 1/2: Blmf, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM (BelaRd)

Click here for details


NCT05060627: Phase 1/2: Belantamab Mafodotin + Kd RRMM Multiple Myeloma, Refractory to Lenalidomide

Click here for details


AMaRC 19-02 - BelaCarD - Phase I/II - Study of combination belantamab maf, carfilzomib, Dex RRMM

Click here for details


NCT03732703: Phase 1/2: Myeloma-Developing Regimens Using Genomics (MyDRUG)

Click here for details


Posts Archive